BACKGROUND: Statins are a commonly used cholesterol-lowering drug, which also have the potential to affect cancer risk and progression. Results from previous studies offer mixed conclusions. METHODS: To evaluate the relation between statin use and prostate cancer risk, we conducted a retrospective cohort study during 1 January 1990 to 31 August 2005 among men 45-79 years receiving care within Group Health, an integrated healthcare delivery system. Information on statin use and covariates were obtained from health plan databases. We identified incident prostate cancer cases through the Surveillance, Epidemiology, and End Results cancer registry. We used Cox proportional hazards models to estimate the hazard ratios (HR) and 95% confidence intervals (CI) for prostate cancer among statin users compared to non-users. RESULTS: Among 83,372 men studied, median follow-up time was 5.7 years and 2,532 prostate cancer cases were identified. About 14.4% used statins over the study period and median duration of use was 3.3 years. Compared to non-users, hydrophobic statin users had a reduced risk of prostate cancer (HR = 0.79; 95% CI, 0.66-0.94), and results are suggestive of a reduced risk among ever users of statins (HR = 0.88; 95% CI, 0.76-1.02) and hydrophilic statin users (HR = 0.67; 95% CI, 0.33-1.34). There was no trend in risk by duration of statin use, and no association between statin use and cancer aggressiveness, stage, or grade. CONCLUSION: Overall, this study does not support an associated between statin use and prostate cancer but a reduced risk cannot be ruled out.
BACKGROUND: Statins are a commonly used cholesterol-lowering drug, which also have the potential to affect cancer risk and progression. Results from previous studies offer mixed conclusions. METHODS: To evaluate the relation between statin use and prostate cancer risk, we conducted a retrospective cohort study during 1 January 1990 to 31 August 2005 among men 45-79 years receiving care within Group Health, an integrated healthcare delivery system. Information on statin use and covariates were obtained from health plan databases. We identified incident prostate cancer cases through the Surveillance, Epidemiology, and End Results cancer registry. We used Cox proportional hazards models to estimate the hazard ratios (HR) and 95% confidence intervals (CI) for prostate cancer among statin users compared to non-users. RESULTS: Among 83,372 men studied, median follow-up time was 5.7 years and 2,532 prostate cancer cases were identified. About 14.4% used statins over the study period and median duration of use was 3.3 years. Compared to non-users, hydrophobic statin users had a reduced risk of prostate cancer (HR = 0.79; 95% CI, 0.66-0.94), and results are suggestive of a reduced risk among ever users of statins (HR = 0.88; 95% CI, 0.76-1.02) and hydrophilic statin users (HR = 0.67; 95% CI, 0.33-1.34). There was no trend in risk by duration of statin use, and no association between statin use and cancer aggressiveness, stage, or grade. CONCLUSION: Overall, this study does not support an associated between statin use and prostate cancer but a reduced risk cannot be ruled out.
Authors: Matthijs R Graaf; Annette B Beiderbeck; Antoine C G Egberts; Dick J Richel; Henk-Jan Guchelaar Journal: J Clin Oncol Date: 2004-06-15 Impact factor: 44.544
Authors: Denise M Boudreau; Mark P Doescher; J Elizabeth Jackson; Paul A Fishman; Barry G Saver Journal: Ann Pharmacother Date: 2004-05-18 Impact factor: 3.154
Authors: Stephen H Taplin; Laura Ichikawa; Diana S M Buist; Deborah Seger; Emily White Journal: Cancer Epidemiol Biomarkers Prev Date: 2004-02 Impact factor: 4.254
Authors: J H Olsen; C Johansen; H T Sørensen; J K McLaughlin; L Mellemkjaer; F H Steffensen; J F Fraumeni Journal: J Clin Epidemiol Date: 1999-02 Impact factor: 6.437
Authors: Patricia F Coogan; Lynn Rosenberg; Julie R Palmer; Brian L Strom; Ann G Zauber; Samuel Shapiro Journal: Epidemiology Date: 2002-05 Impact factor: 4.822
Authors: Wildon R Farwell; Leonard W D'Avolio; Richard E Scranton; Elizabeth V Lawler; J Michael Gaziano Journal: J Natl Cancer Inst Date: 2011-04-15 Impact factor: 13.506
Authors: Thomas P Ahern; Lars Pedersen; Maja Tarp; Deirdre P Cronin-Fenton; Jens Peter Garne; Rebecca A Silliman; Henrik Toft Sørensen; Timothy L Lash Journal: J Natl Cancer Inst Date: 2011-08-02 Impact factor: 13.506
Authors: Zhenshi Wang; Lanyue Zhang; Zheng Wan; Yan He; Huarong Huang; Hongping Xiang; Xiaofeng Wu; Kun Zhang; Yang Liu; Susan Goodin; Zhiyun Du; Xi Zheng Journal: Pathol Oncol Res Date: 2018-05-24 Impact factor: 3.201
Authors: Elizabeth A Platz; Cathee Till; Phyllis J Goodman; Howard L Parnes; William D Figg; Demetrius Albanes; Marian L Neuhouser; Eric A Klein; Ian M Thompson; Alan R Kristal Journal: Cancer Epidemiol Biomarkers Prev Date: 2009-11-03 Impact factor: 4.254
Authors: Aditya Bardia; Elizabeth A Platz; Srinivasan Yegnasubramanian; Angelo M De Marzo; William G Nelson Journal: Curr Opin Pharmacol Date: 2009-07-01 Impact factor: 5.547